Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib
This study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through differe...
Gespeichert in:
| Veröffentlicht in: | Polymers for advanced technologies 2023-04, Vol.34 (4), p.1358-1366 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1366 |
|---|---|
| container_issue | 4 |
| container_start_page | 1358 |
| container_title | Polymers for advanced technologies |
| container_volume | 34 |
| creator | Asadi, Parvin Taymouri, Somayeh Khodarahmi, Ghadamali Jalali, Hanieh Zaker, Hoorieh Sadeghi‐Aliabadi, Hojjat Dinari, Mohammad |
| description | This study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through different techniques. Imatinib (IMA) were loaded thoroughly into the CTF to form IMA‐loaded CTF (IMA@CTF) in which drug loading and encapsulation efficiency was calculated to be 82% and 96%, respectively. The releases of 73% and 48%% after 72 h for the IMA@CTF were obtained in pH = 5.3 and pH = 7.4, respectively, which reflected pH‐dependent behavior as well as sustained imatinib release. Biocompatibility and cytotoxicity effect of CTF and IMA@CTF assessed after 48 h incubation with normal cell line L929 as well as K562 cells. The biocompatibility study indicated reasonable biosafety of the synthesized CTF and MTT assay on chronic myeloma cancer cells showed no reduction effect in the anticancer activity of IMA after incorporating into CTF. The results demonstrated the synthesized CTF could be as a promise anti‐cancer drug carrier. |
| doi_str_mv | 10.1002/pat.5975 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2787098888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2787098888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2935-e4b26dd8d9d9db9d15745d858c9adb0e2f22fedb4577cf890923924f697d04863</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMoWKvgTwh48bI1STdNcizFLyjqoZ5DdjOB1G1Sk21L_fWmrVdnDjPMPPPBi9AtJSNKCHtYm37EleBnaECJUhXlkp4f8ppVgtbiEl3lvCSk9JQYoPgWt9DhYELMrekAb03wXecDbkwGi9u4LdXQ4z558-MDYJfMCnYxfWGTscHhON-alDwk7GLCeZN7U0iLE3RQtuDosF-Z3gffXKMLZ7oMN39xiD6fHhezl2r-_vw6m86rlqkxr6Bu2MRaaVXxRlnKRc2t5LJVxjYEmGPMgW1qLkTrpCKKjRWr3UQJS2o5GQ_R3WnvOsXvDeReL-MmhXJSMyEFUbJYoe5PVJtizgmcXqfyadprSvRBTl3k1Ac5C1qd0J3vYP8vpz-miyP_C9qzeBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2787098888</pqid></control><display><type>article</type><title>Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib</title><source>Access via Wiley Online Library</source><creator>Asadi, Parvin ; Taymouri, Somayeh ; Khodarahmi, Ghadamali ; Jalali, Hanieh ; Zaker, Hoorieh ; Sadeghi‐Aliabadi, Hojjat ; Dinari, Mohammad</creator><creatorcontrib>Asadi, Parvin ; Taymouri, Somayeh ; Khodarahmi, Ghadamali ; Jalali, Hanieh ; Zaker, Hoorieh ; Sadeghi‐Aliabadi, Hojjat ; Dinari, Mohammad</creatorcontrib><description>This study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through different techniques. Imatinib (IMA) were loaded thoroughly into the CTF to form IMA‐loaded CTF (IMA@CTF) in which drug loading and encapsulation efficiency was calculated to be 82% and 96%, respectively. The releases of 73% and 48%% after 72 h for the IMA@CTF were obtained in pH = 5.3 and pH = 7.4, respectively, which reflected pH‐dependent behavior as well as sustained imatinib release. Biocompatibility and cytotoxicity effect of CTF and IMA@CTF assessed after 48 h incubation with normal cell line L929 as well as K562 cells. The biocompatibility study indicated reasonable biosafety of the synthesized CTF and MTT assay on chronic myeloma cancer cells showed no reduction effect in the anticancer activity of IMA after incorporating into CTF. The results demonstrated the synthesized CTF could be as a promise anti‐cancer drug carrier.</description><identifier>ISSN: 1042-7147</identifier><identifier>EISSN: 1099-1581</identifier><identifier>DOI: 10.1002/pat.5975</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Anticancer properties ; Biocompatibility ; Cancer ; covalent organic frameworks ; Drug carriers ; drug delivery ; imatinib ; Nanomaterials ; porous materials ; Structural analysis ; Sustained release ; synthesis ; Toxicity ; Vanillin</subject><ispartof>Polymers for advanced technologies, 2023-04, Vol.34 (4), p.1358-1366</ispartof><rights>2023 John Wiley & Sons Ltd.</rights><rights>2023 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2935-e4b26dd8d9d9db9d15745d858c9adb0e2f22fedb4577cf890923924f697d04863</citedby><cites>FETCH-LOGICAL-c2935-e4b26dd8d9d9db9d15745d858c9adb0e2f22fedb4577cf890923924f697d04863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpat.5975$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpat.5975$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids></links><search><creatorcontrib>Asadi, Parvin</creatorcontrib><creatorcontrib>Taymouri, Somayeh</creatorcontrib><creatorcontrib>Khodarahmi, Ghadamali</creatorcontrib><creatorcontrib>Jalali, Hanieh</creatorcontrib><creatorcontrib>Zaker, Hoorieh</creatorcontrib><creatorcontrib>Sadeghi‐Aliabadi, Hojjat</creatorcontrib><creatorcontrib>Dinari, Mohammad</creatorcontrib><title>Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib</title><title>Polymers for advanced technologies</title><description>This study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through different techniques. Imatinib (IMA) were loaded thoroughly into the CTF to form IMA‐loaded CTF (IMA@CTF) in which drug loading and encapsulation efficiency was calculated to be 82% and 96%, respectively. The releases of 73% and 48%% after 72 h for the IMA@CTF were obtained in pH = 5.3 and pH = 7.4, respectively, which reflected pH‐dependent behavior as well as sustained imatinib release. Biocompatibility and cytotoxicity effect of CTF and IMA@CTF assessed after 48 h incubation with normal cell line L929 as well as K562 cells. The biocompatibility study indicated reasonable biosafety of the synthesized CTF and MTT assay on chronic myeloma cancer cells showed no reduction effect in the anticancer activity of IMA after incorporating into CTF. The results demonstrated the synthesized CTF could be as a promise anti‐cancer drug carrier.</description><subject>Anticancer properties</subject><subject>Biocompatibility</subject><subject>Cancer</subject><subject>covalent organic frameworks</subject><subject>Drug carriers</subject><subject>drug delivery</subject><subject>imatinib</subject><subject>Nanomaterials</subject><subject>porous materials</subject><subject>Structural analysis</subject><subject>Sustained release</subject><subject>synthesis</subject><subject>Toxicity</subject><subject>Vanillin</subject><issn>1042-7147</issn><issn>1099-1581</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEQhoMoWKvgTwh48bI1STdNcizFLyjqoZ5DdjOB1G1Sk21L_fWmrVdnDjPMPPPBi9AtJSNKCHtYm37EleBnaECJUhXlkp4f8ppVgtbiEl3lvCSk9JQYoPgWt9DhYELMrekAb03wXecDbkwGi9u4LdXQ4z558-MDYJfMCnYxfWGTscHhON-alDwk7GLCeZN7U0iLE3RQtuDosF-Z3gffXKMLZ7oMN39xiD6fHhezl2r-_vw6m86rlqkxr6Bu2MRaaVXxRlnKRc2t5LJVxjYEmGPMgW1qLkTrpCKKjRWr3UQJS2o5GQ_R3WnvOsXvDeReL-MmhXJSMyEFUbJYoe5PVJtizgmcXqfyadprSvRBTl3k1Ac5C1qd0J3vYP8vpz-miyP_C9qzeBQ</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Asadi, Parvin</creator><creator>Taymouri, Somayeh</creator><creator>Khodarahmi, Ghadamali</creator><creator>Jalali, Hanieh</creator><creator>Zaker, Hoorieh</creator><creator>Sadeghi‐Aliabadi, Hojjat</creator><creator>Dinari, Mohammad</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8FD</scope><scope>JG9</scope></search><sort><creationdate>202304</creationdate><title>Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib</title><author>Asadi, Parvin ; Taymouri, Somayeh ; Khodarahmi, Ghadamali ; Jalali, Hanieh ; Zaker, Hoorieh ; Sadeghi‐Aliabadi, Hojjat ; Dinari, Mohammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2935-e4b26dd8d9d9db9d15745d858c9adb0e2f22fedb4577cf890923924f697d04863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anticancer properties</topic><topic>Biocompatibility</topic><topic>Cancer</topic><topic>covalent organic frameworks</topic><topic>Drug carriers</topic><topic>drug delivery</topic><topic>imatinib</topic><topic>Nanomaterials</topic><topic>porous materials</topic><topic>Structural analysis</topic><topic>Sustained release</topic><topic>synthesis</topic><topic>Toxicity</topic><topic>Vanillin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Asadi, Parvin</creatorcontrib><creatorcontrib>Taymouri, Somayeh</creatorcontrib><creatorcontrib>Khodarahmi, Ghadamali</creatorcontrib><creatorcontrib>Jalali, Hanieh</creatorcontrib><creatorcontrib>Zaker, Hoorieh</creatorcontrib><creatorcontrib>Sadeghi‐Aliabadi, Hojjat</creatorcontrib><creatorcontrib>Dinari, Mohammad</creatorcontrib><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><jtitle>Polymers for advanced technologies</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Asadi, Parvin</au><au>Taymouri, Somayeh</au><au>Khodarahmi, Ghadamali</au><au>Jalali, Hanieh</au><au>Zaker, Hoorieh</au><au>Sadeghi‐Aliabadi, Hojjat</au><au>Dinari, Mohammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib</atitle><jtitle>Polymers for advanced technologies</jtitle><date>2023-04</date><risdate>2023</risdate><volume>34</volume><issue>4</issue><spage>1358</spage><epage>1366</epage><pages>1358-1366</pages><issn>1042-7147</issn><eissn>1099-1581</eissn><abstract>This study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through different techniques. Imatinib (IMA) were loaded thoroughly into the CTF to form IMA‐loaded CTF (IMA@CTF) in which drug loading and encapsulation efficiency was calculated to be 82% and 96%, respectively. The releases of 73% and 48%% after 72 h for the IMA@CTF were obtained in pH = 5.3 and pH = 7.4, respectively, which reflected pH‐dependent behavior as well as sustained imatinib release. Biocompatibility and cytotoxicity effect of CTF and IMA@CTF assessed after 48 h incubation with normal cell line L929 as well as K562 cells. The biocompatibility study indicated reasonable biosafety of the synthesized CTF and MTT assay on chronic myeloma cancer cells showed no reduction effect in the anticancer activity of IMA after incorporating into CTF. The results demonstrated the synthesized CTF could be as a promise anti‐cancer drug carrier.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><doi>10.1002/pat.5975</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-7147 |
| ispartof | Polymers for advanced technologies, 2023-04, Vol.34 (4), p.1358-1366 |
| issn | 1042-7147 1099-1581 |
| language | eng |
| recordid | cdi_proquest_journals_2787098888 |
| source | Access via Wiley Online Library |
| subjects | Anticancer properties Biocompatibility Cancer covalent organic frameworks Drug carriers drug delivery imatinib Nanomaterials porous materials Structural analysis Sustained release synthesis Toxicity Vanillin |
| title | Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T18%3A42%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20nanoscale%20vanillin%20based%20covalent%20triazine%20framework%20as%20a%20novel%20carrier%20for%20sustained%20release%20of%20imatinib&rft.jtitle=Polymers%20for%20advanced%20technologies&rft.au=Asadi,%20Parvin&rft.date=2023-04&rft.volume=34&rft.issue=4&rft.spage=1358&rft.epage=1366&rft.pages=1358-1366&rft.issn=1042-7147&rft.eissn=1099-1581&rft_id=info:doi/10.1002/pat.5975&rft_dat=%3Cproquest_cross%3E2787098888%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2787098888&rft_id=info:pmid/&rfr_iscdi=true |